CN-122005666-A - Application of qi-tonifying and blood-maintaining formula in preparation of medicine for preventing and treating premenstrual syndrome

Abstract

The invention provides an application of a qi-tonifying and blood-maintaining prescription in preparing a medicine for preventing and treating premenstrual syndrome, and relates to the technical field of medicines. In the application, the active ingredients of the qi-tonifying and blood-maintaining prescription comprise pig blood extract, astragalus and jujube. The invention adopts pig blood extract, astragalus root and jujube to prepare the medicine for preventing and treating premenstrual syndrome, thereby exerting the compatibility advantages of tonifying qi and nourishing blood. The combination breaks through the defect of single target point and large side effect of the traditional hormone and the psychotropic drug, can not only up regulate neurotransmitters to improve emotional abnormalities such as depression anxiety and the like, but also reduce the hypercoagulability state of blood to improve microcirculation through the synergistic regulation of coagulation-inflammation-neuroendocrine network, and realizes the safe and comprehensive intervention of multiple dimensions and multiple systems.

Inventors

• WANG GAOHUA
• ZHANG YANQIONG
• XU YUE
• CHEN KEDIAN
• KONG NA
• WU DAWEI

Assignees

• 广东红珊瑚药业有限公司

Dates

Publication Date

20260512

Application Date

20260324

Claims (10)

1. 1. The application of the qi-tonifying and blood-maintaining prescription in preparing the medicine for preventing and treating premenstrual syndrome is characterized in that the active ingredients of the qi-tonifying and blood-maintaining prescription comprise pig blood extract, astragalus and Chinese dates.
2. 2. The use according to claim 1, wherein the pig blood extract comprises heme iron, and/or, The dosage form of the medicine is an oral preparation, preferably the oral preparation comprises at least one of tablets, capsules, granules, pills, powder, decoction, oral liquid and syrup.
3. 3. The use according to claim 1, wherein the drug is administered in an equivalent dose of 150mg/kg to 750mg/kg.
4. 4. The use according to claim 1, wherein the medicament is for ameliorating depression-like behavior, anxiety-like behavior or symptoms of loss of pleasure caused by the premenstrual syndrome.
5. 5. The use according to claim 1, wherein the medicament treats or prevents premenstrual syndrome by modulating the coagulation-inflammation-neuroendocrine axis and/or by improving systemic oxidative stress and neuroinflammation, modulating brain-gut axis homeostasis.
6. 6. The use of claim 5, wherein said modulation of the coagulation-inflammation-neuroendocrine axis comprises at least one of the pharmacological actions of: A. Upregulating the levels of central neurotransmitters including 5-hydroxytryptamine and norepinephrine, and neurotrophic factors including brain-derived neurotrophic factors; B. Upregulating hormone levels, including estradiol and progesterone; C. Improving blood circulation, reducing blood hypercoagulability and blood stasis tendency; D. Improving systemic oxidative stress and neuroinflammation.
7. 7. The use according to claim 6, wherein said improvement in blood circulation is manifested as an improvement in at least one of the following pharmacological indicators: A. Extending at least one of prothrombin time, thrombin time and activated partial thromboplastin time; B. reducing fibrinogen levels; C. reducing at least one of whole blood viscosity, plasma viscosity, red blood cell pressure, and blood sedimentation.
8. 8. The use of claim 6, wherein said modulation of the coagulation-inflammation-neuroendocrine axis further comprises an improvement in the immune-inflammation index, in particular an improvement in at least one of the following pharmacological indexes: A. Reducing interleukin-6 in serum; B. Upregulating the percentage of monocytes in the blood; C. reducing malondialdehyde levels in serum; D. Up-regulating superoxide dismutase level and/or reduced glutathione to oxidized glutathione ratio in serum.
9. 9. The use of claim 1, wherein the medicament is for upregulating mean hematocrit and/or mean erythrocyte hemoglobin concentration in a subject.
10. 10. The use according to claim 1, wherein the medicament is for upregulating at least one of the following indicators: A. serum and liver tissue coagulation factor IX content of the subject of interest; B. mRNA expression levels of PLCD3 in hippocampal and uterine tissues; C. protein expression levels of hippocampal tissue CAMK2G and SNCAIP; D. MRNA expression levels of NFE2L2, HMOX1 and SOD1 in hippocampal tissues of the subject of interest.

Description

Application of qi-tonifying and blood-maintaining formula in preparation of medicine for preventing and treating premenstrual syndrome Technical Field The invention relates to the technical field of medicines, in particular to an application of a qi-tonifying and blood-maintaining prescription in preparing medicines for preventing and treating premenstrual syndrome. Background Premenstrual syndrome refers to a symptom of repeated occurrence of women in the spirit, behavior, constitution and the like of the luteal phase of the menstrual cycle, and usually self-eases or disappears with the beginning or ending of the next menstrual cycle. Premenstrual syndrome is a disease with higher incidence rate in women of childbearing age, and related epidemiological data at home and abroad indicate that the disease has higher incidence rate, wherein the physical discomfort of partial patients and emotional symptoms such as depression, anxiety and the like can seriously influence the normal life and working state of the patients. Thus, there has been a great clinical interest in the prevention and effective intervention of premenstrual syndrome. At present, the exact cause and pathogenesis of premenstrual syndrome are not yet fully elucidated, and it is generally thought that imbalance of endocrine hormones such as luteal phase estrogen and progestin may be one of the important factors for the initiation of the syndrome. Aiming at the disease, the existing clinical conventional intervention means are relatively limited and mainly depend on hormone regulating drugs and psychoneurosis drugs. For example, conventional approaches have been to modulate the menstrual cycle by using progesterone or synthetic progestins, or to intervene with combined oral contraceptives. In addition, in patients with marked mood swings, symptomatic treatment with selective serotonin reuptake inhibitors and the like is often carried out clinically, and in rare cases, potent modulators such as gonadotrophin releasing hormone agonists are also considered. However, the above-mentioned existing intervention methods have many limitations and disadvantages in practical clinical applications. On one hand, hormone medicines such as progestogen or contraceptive can regulate hormone level to a certain extent, but the exact curative effect is greatly controversial in a plurality of random control researches, and the long-term exogenous hormone intervention is extremely easy to break the original endocrine and physiological homeostasis of a human body, so as to cause a series of adverse reactions. On the other hand, although the psychotics have a certain pertinence to alleviating part of depression and anxiety symptoms, the target points of the psychotics are single, corresponding tolerance problems or side effects are often accompanied, and complex body and physiological microcirculation abnormality of premenstrual syndrome patients cannot be improved on the whole. In summary, since premenstrual syndrome involves complex pathological changes of multiple systems such as nerves and endocrine, the existing single-target drug or hormone replacement therapy is difficult to realize comprehensive and multidimensional comprehensive conditioning, and the safety and curative effect stability of long-term application are insufficient. The clinical challenges of limited drug selection and poor comprehensive intervention effect are still faced, and a drug preparation scheme capable of safely, systematically improving various complex symptoms of premenstrual syndrome in multiple ways is needed to be searched. In view of this, the present invention has been made. Disclosure of Invention The invention aims to provide an application of a qi-tonifying and blood-maintaining formula in preparing a medicine for preventing and treating premenstrual syndrome, which realizes multidimensional safety regulation and control of premenstrual syndrome coagulation-inflammation-neuroendocrine network through the synergistic effect of pig blood extract, astragalus and Chinese date, effectively improves mood abnormality and microcirculation disturbance, and overcomes the defect of large side effect of the existing single-target medicine. In order to achieve the above object of the present invention, the following technical solutions are specifically adopted: The invention provides an application of a qi-tonifying and blood-maintaining formula in preparing a medicine for preventing and treating premenstrual syndrome, wherein active ingredients of the qi-tonifying and blood-maintaining formula comprise pig blood extract, astragalus and Chinese dates. In alternative embodiments, the pig blood extract comprises heme iron, and/or, The dosage form of the medicine is an oral preparation, preferably the oral preparation comprises at least one of tablets, capsules, granules, pills, powder, decoction, oral liquid and syrup. In an alternative embodiment, the drug is administered in an equivalent dose